- Zacks•3 days ago
Huge implied volatility makes Tetraphase Pharmaceuticals (TTPH) Stock lucrative to the option traders.
- GlobeNewswire•3 days ago
Tetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WATERTOWN, Mass., April 21, 2017-- Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, today ...
- GlobeNewswire•21 days ago
Tetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
Accelerated Timelines for Both Top-line IGNITE4 Eravacycline Data and MAA filing in Europe; Both Now Expected in 3 Q 2017. IGNITE4 Results to Support U.S. NDA Filing for IV Eravacycline in cIAI.
TTPH : Summary for Tetraphase Pharmaceuticals, Inc - Yahoo Finance
Tetraphase Pharmaceuticals, Inc. (TTPH)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||8.10 x 1800|
|Ask||8.12 x 500|
|Day's Range||7.85 - 8.23|
|52 Week Range||3.11 - 9.93|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.84|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|